Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program

por Rossignol, Patrick, David, Lea, Chan, Christine, Conrad, Ansgar, Weir, Matthew R.
Publicado 2021

Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors

por Kloner, Robert A., Gross, Coleman, Yuan, Jinwei, Conrad, Ansgar, Pergola, Pablo E.
Publicado 2018

Association Between Hematologic Response and Change in Health-Related Quality of Life Among Patients with Light-Chain (AL) Amyloidosis

por Rizio, Avery A, McCausland, Kristen L, Carty, Michelle K, Conrad, Ansgar, Quock, Tiffany P
Publicado 2023

PB2135: TREATMENT PATTERNS IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS

por D’souza, Anita, Quock, Tiffany, Conrad, Ansgar, Broder, Michael S, Das, Ashis K., Chang, Eunice, Tarbox, Marian H.
Publicado 2023

PB2154: THE IMPACT OF DISEASE SEVERITY ON THE CLINICAL AND ECONOMIC BURDEN OF AL AMYLOIDOSIS

por D’souza, Anita, Quock, Tiffany, Conrad, Ansgar, Broder, Michael S., Das, Ashis K., Chang, Eunice, Tarbox, Marian H.
Publicado 2023

Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients

por Kovesdy, Csaba P., Rowan, Christopher G., Conrad, Ansgar, Spiegel, David M., Fogli, Jeanene, Oestreicher, Nina, Connaire, Jeffrey J., Winkelmayer, Wolfgang C.
Publicado 2018